2025-01-26 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis Report

**1. Performance Comparison and Divergence:**

Eli Lilly and Co. (LLY) is a leading pharmaceutical company, developing and manufacturing medicines and biomedicines globally.

LLY's cumulative return (566.99%) significantly outperforms the S&P 500 (VOO) cumulative return (52.12%) over the analyzed period. The difference in cumulative returns is 514.9%, placing LLY at the 71.8th percentile of its historical performance relative to the S&P 500 based on the provided range (max: 699.7, min: 44.2).  The provided CAGR figures further highlight LLY's substantial outperformance relative to the market benchmark.

**Alpha/Beta Analysis:**  The consistently high CAGR (180%-396%), alongside an Alpha consistently around 1.0, indicates significant outperformance compared to the market (S&P 500). A Beta of 1.0 suggests that LLY's price movements generally mirror the market, although the high alpha demonstrates substantial outperformance.  The relatively low maximum drawdown (MDD) across all periods suggests comparatively lower risk despite the high returns. The steadily increasing market capitalization (Cap(B)) reflects the company's growth.


**2. Recent Price Movement:**

* **Closing Price:** $785.41
* **5-Day Moving Average:** $754.81
* **20-Day Moving Average:** $771.26
* **60-Day Moving Average:** $787.66

The price is slightly below the 60-day moving average, suggesting a potential short-term pullback.  However, the price is above both the 5-day and 20-day moving averages, indicating a generally upward trend in the short-to-medium term.  The recent price increase (+$2.45 from the previous close) indicates a positive market sentiment.

**3. Technical Indicators and Expected Return:**

* **RSI:** 51.71 – This indicates a neutral market sentiment.  It's neither overbought nor oversold.
* **PPO:** 0.16 – A positive PPO suggests upward momentum.
* **Delta_Previous_Relative_Divergence:** +3.0 –  This positive value confirms the short-term upward trend.
* **Expected Return:** 146.3% –  This projection suggests significantly higher returns compared to the S&P 500 over a long-term (2+ years) investment horizon.  The high projected return is consistent with the past performance metrics.  Note that this is just an estimate and future performance is never guaranteed.

**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue        |
|------------|--------|----------------|
| 2024-10-30 | $1.08  | $11.44B        |
| 2024-08-08 | $3.29  | $11.30B        |
| 2024-04-30 | $2.49  | $8.77B         |
| 2023-11-02 | -$0.06 | $9.50B         |
| 2024-10-30 | -$0.06 | $9.50B         |

There appears to be a duplicate entry for October 30, 2024. Assuming this is an error and using the first entry, earnings show significant variability. Revenue generally remains strong, but EPS fluctuates considerably, suggesting some inconsistency in profitability across quarters.  Further investigation into the reasons for this fluctuation would be beneficial.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter     | Revenue   | Profit Margin |
|-------------|-----------|---------------|
| 2024-09-30  | $11.44B  | 81.02%        |
| 2024-06-30  | $11.30B  | 80.80%        |
| 2024-03-31  | $8.77B   | 80.91%        |
| 2023-12-31  | $9.35B   | 80.88%        |
| 2023-09-30  | $9.50B   | 80.42%        |

Revenue is generally stable and high, with the exception of Q1 2024. Profit margins remain consistently high, indicating strong profitability.

**Capital and Profitability:**

| Quarter     | Equity    | ROE           |
|-------------|-----------|---------------|
| 2024-09-30  | $14.24B  | 6.81%         |
| 2024-06-30  | $13.56B  | 21.88%        |
| 2024-03-31  | $12.81B  | 17.51%        |
| 2023-12-31  | $10.77B  | 20.33%        |
| 2023-09-30  | $11.22B  | -0.51%        |

Equity is increasing, but ROE shows significant variability, mirroring the EPS volatility.  The negative ROE in Q3 2023 requires further investigation.


**7. Overall Analysis:**

LLY demonstrates exceptional historical performance significantly outpacing the S&P 500.  While recent price action shows a slight pullback, technical indicators suggest a neutral to positive outlook in the short term.  The high projected long-term return and generally strong financial performance (despite some quarterly volatility) present a compelling investment case. However, the fluctuating EPS and ROE warrant further investigation to understand the underlying drivers and potential risks.  A deeper dive into the specific factors influencing quarterly earnings and the reasons for the negative ROE in Q3 2023 is recommended before making any investment decisions.  The high projected return should be viewed cautiously as past performance is not indicative of future results.

**8. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  Conduct thorough due diligence and consult with a financial professional before making any investment decisions.
